VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
AGL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
AGLAgilon Health, Inc.
$115.20$1.9B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksAGLBalance Sheet

Agilon Health, Inc. (AGL) Balance Sheet

7Y historyFree accessUpdated daily

Total debt has held near $33M to $46M with a debt-to-equity ratio of 0.12, but the current ratio of 1.13 and equity falling from $676.6M to $126.7M before partially rebounding indicate a thin liquidity and capital cushion.

Income StatementBalance SheetCash FlowRatios

AGL Balance Sheet

Annual statement

AGL Balance Sheet

Agilon Health, Inc. (AGL) balance sheet — 7-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19
Total Current Assets1.4B1.1B1.46B1.48B1.45B1.37B294.2M245.53M
Cash & Short-Term Investments239.76M285.14M405.6M495.1M877.2M1.05B106.8M123.63M
Cash Only174.4M173.71M193.86M114.33M465.3M1.05B106.8M123.63M
Short-Term Investments65.36M111.43M211.74M380.77M411.9M000
Accounts Receivable1.02B673.79M1.02B942.46M492.36M293.41M144.56M93.25M
Days Sales Outstanding55.4841.4561.2579.775.2570.3943.3142.85
Inventory00000000
Days Inventory Outstanding--------
Other Current Assets142.91M137.76M35.14M42.51M81.71M18.97M33.21M24.33M
Total Non-Current Assets165.73M174.59M276.21M260.79M246.19M219.06M152.16M157.27M
Property, Plant & Equipment28.48M25.42M36.95M40.99M31.95M20.9M16.04M18.84M
Fixed Asset Turnover211.75x233.41x164.01x105.31x74.74x72.80x75.95x42.18x
Goodwill0024.13M24.13M2.51M41.54M41.54M41.54M
Intangible Assets56.85M65.72M72.77M63.77M18.45M55.4M60.47M71.15M
Long-Term Investments260.98M59.79M61.76M44.75M17.35M6.69M8.5M0
Other Non-Current Assets16.43M23.66M80.6M87.15M175.93M94.53M25.61M25.74M
Total Assets1.57B1.27B1.73B1.74B1.7B1.59B446.36M402.79M
Asset Turnover4.05x4.67x3.50x2.48x1.41x0.96x2.73x1.97x
Asset Growth %-57.84%-26.68%-0.4%2.56%7.01%255.37%10.82%-
Total Current Liabilities1.23B1.08B1.15B977.16M535.09M356.96M266.83M199.61M
Accounts Payable325.96M1.06B1.15B968.06M478.23M348.65M260.11M188.26M
Days Payables Outstanding45.5763.0469.2983.276.6687.4284.4589.72
Short-Term Debt15.02M19.24M2.46M9.1M5M8.31M3.04M3.04M
Deferred Revenue (Current)00000000
Other Current Liabilities000051.87M03.68M8.31M
Current Ratio1.13x1.02x1.27x1.51x2.71x3.83x1.10x1.23x
Quick Ratio1.13x1.02x1.27x1.51x2.71x3.83x1.10x1.23x
Cash Conversion Cycle9.91-------
Total Non-Current Liabilities51.33M68.07M111.02M102.69M121.77M137.7M464.26M435.21M
Long-Term Debt15.51M15.75M34.9M32.31M38.48M43.4M64.67M67.14M
Capital Lease Obligations11.25M1.83M6.6M10.9M9.09M7.9M5.51M7.74M
Deferred Tax Liabilities00000010.01M12.82M
Other Non-Current Liabilities32.92M50.49M69.52M59.48M74.19M86.39M384.07M347.51M
Total Liabilities1.28B1.14B1.26B1.08B656.86M494.66M731.09M634.82M
Total Debt33.42M36.81M43.96M52.31M52.57M59.61M73.21M77.92M
Net Debt-140.97M-136.9M-149.9M-62.02M-412.73M-995.21M-33.58M-45.71M
Debt / Equity0.12x0.29x0.09x0.08x0.05x0.05x--
Debt / EBITDA-0.41x-------
Net Debt / EBITDA1.71x-------
Interest Coverage-34.60x-59.85x-39.28x-28.21x-19.22x-61.31x-6.66x-11.65x
Total Equity280.88M126.73M470.95M661.02M1.04B1.09B-284.73M-232.03M
Equity Growth %-189.42%-73.09%-28.75%-36.48%-4.67%483.38%-22.71%-
Book Value per Share15.887.6528.6540.4163.7473.18-18.50-15.11
Total Shareholders' Equity280.88M126.73M470.95M661.84M1.04B1.09B-284.73M-232.03M
Common Stock168K4.15M4.12M4.06M4.12M4M2.49M2.47M
Retained Earnings-1.88B-1.98B-1.59B-1.33B-1.06B-957.68M-551.19M-491.14M
Treasury Stock00000000
Accumulated OCI-143K916K-88K-2.3M-5.56M000
Minority Interest000-818K-611K-300K00

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Negative margins and equity erosion

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Equity Eroding as Cushion Thins

Based on AGL's reported figures, shareholders' equity fell from $676.6M in Q2 2024 to $126.7M in Q4 2025 before partially rebounding to $280.9M in Q3 2026, a pattern that suggests the balance sheet cushion has narrowed materially over the period.

The decline in equity appears driven by sustained operating losses rather than leverage, since accumulated deficit stayed near -$1.9B throughout the window. The Q3 2026 rebound is encouraging but reflects a single quarter, so investors should monitor whether equity stabilizes or whether further losses reverse the recovery.

Current Ratio Near Breakeven Level

According to reported balance sheet figures, AGL's current ratio declined from 1.36 in Q2 2024 to 1.02 in Q4 2025 and recovered only modestly to 1.13 in Q3 2026, leaving a thin margin of current assets over current liabilities.

Cash of $174.4M in Q3 2026 provides some buffer, but the ratio suggests limited headroom to absorb an unexpected rise in medical claims payable or a timing mismatch in payer receivables. Given the negative gross margin reported elsewhere in the data, the company's short-term liquidity cushion may be more sensitive to operating drag than the headline ratio implies.

Low Leverage Masks Operating Risk

As reported in financial statements, AGL's total debt has held near $33M to $46M across the ten quarters, producing a debt-to-equity ratio that moved from 0.07 to 0.29 and currently sits at 0.12.

Modest absolute debt and low leverage ratios suggest that financing risk is not the primary constraint on the balance sheet. The rising D/E in late 2025, however, reflects shrinking equity rather than new borrowing, which is a signal of deteriorating capital base rather than strategic leverage.

Asset-Light Profile with Goodwill Swings

Based on AGL's reported figures, goodwill moved from $24.1M to $65.7M and back to $56.9M across recent quarters, while net PP&E stayed in a narrow $25M to $40M range, indicating an asset base dominated by intangibles and light fixed assets.

The goodwill fluctuation implies acquisition or impairment activity that warrants review in the filings, since the change is large relative to the company's equity base. The low PP&E intensity is consistent with a services-oriented model, though it also means the asset base offers limited tangible value in a downside scenario.

Equity Rebound May Prove Transitory

Based on reported figures, the Q3 2026 equity increase to $280.9M from $227.5M may reflect timing or non-operating items rather than durable improvement, given that retained earnings remain near -$1.9B.

A single-quarter equity increase alongside an unchanged accumulated deficit suggests the gain may stem from capital transactions or other non-operating items rather than retained profitability. Investors should examine the equity roll-forward before treating the rebound as evidence of balance sheet repair.

AGL — Frequently Asked Questions

Quick answers to the most common questions about buying AGL stock.

What are the total assets of Agilon Health, Inc. (AGL)?

As of 2025, Agilon Health, Inc. (AGL) had total assets of $1.27B including $1.10B in current assets.

How much debt does Agilon Health, Inc. (AGL) have?

Agilon Health, Inc. (AGL) carries total debt of $36.8M, offset by $285.1M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Agilon Health, Inc.?

Agilon Health, Inc. (AGL) has total shareholders' equity (book value) of $126.7M ($7.65 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Agilon Health, Inc.'s current ratio and liquidity?

Agilon Health, Inc. (AGL) reported a current ratio of 1.02x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.